# Photobiomodulation at 830 nm with 5 J/cm2 does not promote PI3K/AKT/mTOR signalling pathway activation in hyperglycemic wounded cells

**Authors:** Patricia Kasowanjete, Sathish Sundar Dhilip Kumar, Nicolette Houreld

PMC · DOI: 10.1007/s10103-026-04859-8 · Lasers in Medical Science · 2026-03-27

## TL;DR

This study shows that 830 nm photobiomodulation improves wound healing in hyperglycemic cells without activating the PI3K/AKT/mTOR pathway.

## Contribution

The study reveals that PBM promotes wound healing independently of the PI3K/AKT/mTOR pathway in hyperglycemic conditions.

## Key findings

- PBM increased cell migration, viability, and proliferation in hyperglycemic wounded cells.
- The PI3K/AKT/mTOR pathway was not activated by PBM at 830 nm and 5 J/cm².
- Wound healing was enhanced without changes in the PI3K/AKT/mTOR signaling pathway.

## Abstract

The phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), mammalian target of rapamycin (mTOR) (PI3K/AKT/mTOR) pathway regulates cell survival, proliferation, and the synthesis of protein. Photobiomodulation (PBM) stimulates biological processes by using low-powered light in the visible, red and near-infrared (NIR) spectrum. Despite its demonstrated efficacy, the cellular and molecular consequences, primarily on the PI3K/AKT/mTOR pathway, remain unclear. This study investigated PBMs impact on the PI3K/AKT/mTOR pathway in fibroblast (WS1) cells modelled as normal (N), wounded (W), hyperglycemic (D), hyperglycemic wounded (DW), and hyperglycemic hypoxic wounded (DHW). Non-irradiated cells served as controls. PBM was applied using an 830 nm diode at 5 J/cm2. Cellular changes at 24 and 48 h post-PBM were assessed via the Trypan blue exclusion assay (viability), light microscopy (morphology and migration), flow cytometry (proliferation and apoptosis), and the enzyme linked immunosorbent assay (ELISA) and western blot (VEGF, Bcl-2, PI3K, AKT, mTOR and GSK3β). PBM enhanced cellular migration rate, viability, and proliferation, without altering the PI3K/AKT/mTOR pathway. PBM at 830 nm with 5 J/cm2 promoted wound healing independently of the PI3K/AKT/mTOR pathway.

The online version contains supplementary material available at 10.1007/s10103-026-04859-8.

## Linked entities

- **Proteins:** PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), AKT1 (AKT serine/threonine kinase 1), MTOR (mechanistic target of rapamycin kinase), VEGFA (vascular endothelial growth factor A), BCL2 (BCL2 apoptosis regulator), GSK3B (glycogen synthase kinase 3 beta)

## Full-text entities

- **Genes:** PDK1 (pyruvate dehydrogenase kinase 1) [NCBI Gene 5163], ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, COX8A (cytochrome c oxidase subunit 8A) [NCBI Gene 1351] {aka COX, COX8, COX8-2, COX8L, MC4DN15, VIII}, CASP6 (caspase 6) [NCBI Gene 839] {aka CSP-6, MCH2, caspase-6}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Blnk (B cell linker) [NCBI Gene 17060] {aka BASH, Bca, Ly-57, Ly57, Lyw-57, SLP-65}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}
- **Diseases:** pain (MESH:D010146), N (MESH:C536108), hyperglycemic (MESH:D006944), DM (MESH:D003920), Chronic wounds (MESH:D014947), necrosis (MESH:D009336), hyperglycemic hypoxic (MESH:D002534), Hyperglycemia (MESH:D006943), inflammation (MESH:D007249), Hypoxia (MESH:D000860)
- **Chemicals:** FITC (MESH:D016650), propidium iodide (MESH:D011419), thymidine (MESH:D013936), SDS (MESH:D012967), lipids (MESH:D008055), amphotericin B (MESH:D000666), Ser (MESH:D012694), NO (MESH:D009569), AB8932 (-), PIP2 (MESH:D019269), PVDF (MESH:C024865), streptomycin (MESH:D013307), L-glutamine (MESH:D005973), 3,3'-Diaminobenzidine (MESH:D015100), oxygen (MESH:D010100), cAMP (MESH:D000242), actinomycin D (MESH:D003609), CO2 (MESH:D002245), Tween-20 (MESH:D011136), ATP (MESH:D000255), melanin (MESH:D008543), 5-bromo-2'-deoxyuridine (MESH:D001973), TMB (MESH:C021758), D-glucose (MESH:D005947), Laemmli buffer (MESH:C088816), Trypan blue (MESH:D014343), 7-AAD (MESH:C025942), phosphatidylinositol 3,4,5- triphosphate (MESH:C060974), ROS (MESH:D017382), glycogen (MESH:D006003), PI (MESH:D010716), hydrogen peroxide (MESH:D006861), penicillin (MESH:D010406)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Chlorocebus aethiops (African green monkey, species) [taxon 9534], SV40 [taxon 10633]
- **Cell lines:** N — Homo sapiens (Human), Finite cell line (CVCL_UZ57), WS1 — Homo sapiens (Human), Finite cell line (CVCL_2766), fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13021734/full.md

## Figures

20 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13021734/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC13021734/full.md

---
Source: https://tomesphere.com/paper/PMC13021734